Summary:
In adults from pooled SURPASS-1, -2, -3 trials (n=3,792), stratified by early-onset T2D (diagnosed <40 years) vs later-onset (≥40 years), tirzepatide (dual GIP/GLP-1 agonist) for 40-52 weeks achieved comparable improvements in both groups: HbA1c -2.6% vs -2.4%, weight -14 kg vs -13 kg, waist circumference -10 cm, triglycerides -26% vs -24%, SBP -6 vs -7 mmHg compared to later-onset T2D outcomes under identical trial conditions, with robust efficacy regardless of age at diagnosis despite worse baseline metabolic profiles in early-onset patients.
| PICO | Description |
|---|---|
| Population | Adults from SURPASS-1, -2, -3 (n=3,792), stratified by early-onset (<40y) vs later-onset (≥40y) T2D. |
| Intervention | Tirzepatide (dual GIP/GLP-1 agonist) for 40-52 weeks. |
| Comparison | Outcomes in early-onset vs later-onset T2D under identical trial conditions. |
| Outcome | Comparable: HbA1c -2.6% vs -2.4%, weight -14 vs -13 kg, waist -10 cm, TG -26% vs -24%. |
Clinical Context
Early-onset T2D (diagnosed <40y) is more aggressive with worse metabolic profiles and faster complications. Clinical trials often under-enroll younger patients.
Clinical Pearls
1. Early-Onset T2D Responds Equally Well: Comparable or greater improvements despite worse baseline.
2. Worse Baseline Confirms Early-Onset Severity: Higher HbA1c, greater obesity, worse lipids at baseline.
3. Comprehensive Cardiometabolic Improvement: Weight, waist, lipids, BP all improved similarly.
4. Treatment Efficacy Independent of Diagnosis Age: Age at diagnosis did not modify response.
Practical Application
Strongly consider tirzepatide for early-onset T2D given high-risk profile and demonstrated efficacy. Consider earlier aggressive therapy rather than stepwise escalation.
Study Limitations
Post hoc analysis. Arbitrary age cutoff. Long-term outcomes beyond trial duration unknown.
Bottom Line
Early-onset T2D achieves robust, comparable improvements with tirzepatide despite worse baseline profiles.
Source: Zeitler P, et al. “Early-Onset Type 2 Diabetes and Tirzepatide Treatment: SURPASS Post Hoc Analysis.” Diabetes Care. Read article